Transcriptional Enhancer Factor (TEAD): A Promising Drug Target and Potential Biomarker

Target Name: Transcriptional Enhancer Factor (TEAD) (nonspecified subype)

NCBI ID: P33717

Transcriptional Enhancer Factor (TEAD) (nonspecified subype)

Other Name(s): TEA domain family member | TEF | TEAD

Transcriptional Enhancer Factor (TEAD): A Promising Drug Target and Potential Biomarker

Abstract:
Transcriptional Enhancer Factor (TEAD) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression. As a member of the TEAD domain family, TEAD has been identified as a potential drug target and a biomarker for various diseases. This article summarizes the current understanding of TEAD, its potential drug targets, and its potential as a biomarker for disease diagnosis and treatment.

Introduction:
Transcriptional Enhancer Factor (TEAD) is a non-coding RNA molecule that is expressed in various tissues and cells. It is a member of the TEAD domain family, which is characterized by the presence of a conserved catalytic core and a variable binding site that can interact with various protein factors. TEAD has been shown to play a role in the regulation of gene expression and has been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Potential Drug Targets:
TEAD has been identified as a potential drug target due to its unique structure and its ability to interact with various proteins. One of the TEAD domains, the N-terminal domain, has been shown to interact with the protein histamine receptor 7 (GPR73 ), a G protein-coupled receptor that plays a role in the regulation of neural function and pain perception. The interaction between TEAD and GPR73 suggests that TEAD may be a useful drug target for the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another potential drug target for TEAD is the protein Pyruvate Kinase (PK), which is involved in the metabolism of pyruvate, a critical fuel for cellular energy production. TEAD has been shown to interact with PK, which may suggest that it plays a role in the regulation of cellular metabolism and energy production. The inhibition of TEAD activity has been shown to increase the activity of PK, suggesting that TEAD may be a potential drug target for the treatment of metabolic diseases, such as obesity and type 2 diabetes.

Potential Biomarkers:
TEAD has also been identified as a potential biomarker for various diseases. One of the TEAD domains, the C-terminal domain, has been shown to interact with the protein heat shock protein (Hsp90), which is involved in the regulation of protein expression and translation in response to thermal stress. The interaction between TEAD and Hsp90 suggests that TEAD may be a potential biomarker for the diagnosis and treatment of thermal stress-induced diseases, such as cancer and neurodegenerative diseases.

Another potential biomarker for TEAD is its ability to interact with the protein known as p53, a transcription factor that is involved in the regulation of gene expression and DNA damage repair. The interaction between TEAD and p53 suggests that TEAD may be a potential biomarker for the diagnosis and treatment of DNA damage-related diseases, such as cancer.

Conclusion:
In conclusion, TEAD is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and its ability to interact with various proteins make it a promising candidate for drug development. Further research is needed to fully understand the role of TEAD in the regulation of gene expression and its potential as a biomarker for disease diagnosis and treatment.

Protein Name: Transcriptional Enhancer Factor (TEAD) (nonspecified Subype)

The "Transcriptional Enhancer Factor (TEAD) (nonspecified subype) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Transcriptional Enhancer Factor (TEAD) (nonspecified subype) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets